Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi-Aventis, Covance in 10-Year R&D Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi-Aventis, Covance in 10-Year R&D Pact

Covance to acquire Porcheville, Alnwick sites, add CMC, formulation services.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance Inc. and Sanofi-Aventis have signed a 10-year R&D agreement potentially worth more than $2 billion. Covance will provide drug development services to SA and will acquire SA’s Porcheville, France and Alnwick, UK sites and facilities for approximately $25 million. Covance will maintain employment on these sites for at least the next five years.

Characterizing this change in Sanofi’s R&D model,Marc Cluzel, M.D., Ph.D., the company’s executive vice president, R&D, remarked, “This alliance with Covance will help us preserve hundreds of valuable jobs in Porcheville and Alnwick, while driving our R&D efficiency for the benefit of the patients.”

“We look forward to welcoming the world-class scientific talent in Porcheville and Alnwick to Covance, as well as adding state-of-the-art assets and new services to our portfolio,” said Joe Herring, Covance’s chairman and chief executive officer.

Sanofi will utilize Covance’s global R&D offerings in discovery support, toxicology, chemistry, clinical Phase I-IV, central laboratory, and market access services, with annual commitments for services increasing over the next decade. These agreements include a 10-year sole-source relationship for central laboratory services. Covance estimates payments from the deal will range between $1.2 billion and $2.2 billion.

Covance will acquire CMC services with the addition of the Porcheville and Alnwick sites, including preformulation, drug formulation, preclinical and early-stage clinical API manufacturing, and radiolabeled chemistry. The transaction is expected to be completed before the end of the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics